T. Yong

Long-term outcomes of daridorexant in those with comorbid insomnia.

AIMS AND METHOD Daridorexant is a dual orexin receptor antagonist recently licensed for chronic insomnia disorder. Guidelines recommend it as a second-line treatment for insomnia, after cognitive-behavioural therapy. Initial trials excluded common comorbidities despite comorbid insomnia being the norm, not the exceptio...